The FDA regulates BPC-157, a research peptide used for tissue repair and gastrointestinal applications, through its 503A bulk drug substances lists for pharmacy compounding. Previously placed in Category 2 due to immunogenicity risks, impurity concerns, and limited human safety data, the substance was removed from that list in April 2026 after nomination withdrawals, leaving it in regulatory limbo. At the July 23-24, 2026 Pharmacy Compounding Advisory Committee meeting, the panel voted 8-6 (with one abstention) to recommend inclusion on the 503A bulks list, which would enable Category 1 status and interim compounding eligibility. The FDA has not yet issued a final determination, and any move to Category 1 would require agency rulemaking. Traders monitor this process alongside potential future PCAC reviews or policy shifts for resolution timing.
基于Polymarket数据的AI实验性摘要。这不是交易建议，也不影响该市场的结算方式。 · 更新于最新
2026-08-31
2026年8月31日
7%
2026年12月31日
51%
$2,789 交易量
2026年8月31日
$1,083 交易量
7%
2026年12月31日
$1,706 交易量
51%
This market will resolve to “Yes” if the Food and Drug Administration (FDA) announces that it has reclassified or will reclassify BPC-157 to Category 1 of the Bulk Drug Substances List by the listed date, 11:59 PM ET. Otherwise, this market will resolve to “No”.
A qualifying announcement must be official and public. Any rumored or private statements of intention will not qualify.
Any announcement that the drug has been reclassified to Category 1 will qualify. Any announcement within this market’s timeframe of future intention to reclassify to Category 1 will qualify regardless of whether the reclassification has happened by the listed date.
A qualifying reclassification must be to Category 1 of the Bulk Drug Substances List or an equivalent classification that allows interim compounding of the drug. Removal from a different category will not qualify.
The resolution source for this market will be official statements from the FDA; however, a consensus of credible reporting will also be used.The FDA regulates BPC-157, a research peptide used for tissue repair and gastrointestinal applications, through its 503A bulk drug substances lists for pharmacy compounding. Previously placed in Category 2 due to immunogenicity risks, impurity concerns, and limited human safety data, the substance was removed from that list in April 2026 after nomination withdrawals, leaving it in regulatory limbo. At the July 23-24, 2026 Pharmacy Compounding Advisory Committee meeting, the panel voted 8-6 (with one abstention) to recommend inclusion on the 503A bulks list, which would enable Category 1 status and interim compounding eligibility. The FDA has not yet issued a final determination, and any move to Category 1 would require agency rulemaking. Traders monitor this process alongside potential future PCAC reviews or policy shifts for resolution timing.
This market will resolve to “Yes” if the Food and Drug Administration (FDA) announces that it has reclassified or will reclassify BPC-157 to Category 1 of the Bulk Drug Substances List by the listed date, 11:59 PM ET. Otherwise, this market will resolve to “No”.
A qualifying announcement must be official and public. Any rumored or private statements of intention will not qualify.
Any announcement that the drug has been reclassified to Category 1 will qualify. Any announcement within this market’s timeframe of future intention to reclassify to Category 1 will qualify regardless of whether the reclassification has happened by the listed date.
A qualifying reclassification must be to Category 1 of the Bulk Drug Substances List or an equivalent classification that allows interim compounding of the drug. Removal from a different category will not qualify.
The resolution source for this market will be official statements from the FDA; however, a consensus of credible reporting will also be used.
A qualifying announcement must be official and public. Any rumored or private statements of intention will not qualify.
Any announcement that the drug has been reclassified to Category 1 will qualify. Any announcement within this market’s timeframe of future intention to reclassify to Category 1 will qualify regardless of whether the reclassification has happened by the listed date.
A qualifying reclassification must be to Category 1 of the Bulk Drug Substances List or an equivalent classification that allows interim compounding of the drug. Removal from a different category will not qualify.
The resolution source for this market will be official statements from the FDA; however, a consensus of credible reporting will also be used.
市场开放时间： Jun 22, 2026, 10:10 PM ET
交易量
$2,789结束日期
2026-12-31市场开放时间
Jun 22, 2026, 10:10 PM ETResolver
0x65070BE91...This market will resolve to “Yes” if the Food and Drug Administration (FDA) announces that it has reclassified or will reclassify BPC-157 to Category 1 of the Bulk Drug Substances List by the listed date, 11:59 PM ET. Otherwise, this market will resolve to “No”.
A qualifying announcement must be official and public. Any rumored or private statements of intention will not qualify.
Any announcement that the drug has been reclassified to Category 1 will qualify. Any announcement within this market’s timeframe of future intention to reclassify to Category 1 will qualify regardless of whether the reclassification has happened by the listed date.
A qualifying reclassification must be to Category 1 of the Bulk Drug Substances List or an equivalent classification that allows interim compounding of the drug. Removal from a different category will not qualify.
The resolution source for this market will be official statements from the FDA; however, a consensus of credible reporting will also be used.The FDA regulates BPC-157, a research peptide used for tissue repair and gastrointestinal applications, through its 503A bulk drug substances lists for pharmacy compounding. Previously placed in Category 2 due to immunogenicity risks, impurity concerns, and limited human safety data, the substance was removed from that list in April 2026 after nomination withdrawals, leaving it in regulatory limbo. At the July 23-24, 2026 Pharmacy Compounding Advisory Committee meeting, the panel voted 8-6 (with one abstention) to recommend inclusion on the 503A bulks list, which would enable Category 1 status and interim compounding eligibility. The FDA has not yet issued a final determination, and any move to Category 1 would require agency rulemaking. Traders monitor this process alongside potential future PCAC reviews or policy shifts for resolution timing.
This market will resolve to “Yes” if the Food and Drug Administration (FDA) announces that it has reclassified or will reclassify BPC-157 to Category 1 of the Bulk Drug Substances List by the listed date, 11:59 PM ET. Otherwise, this market will resolve to “No”.
A qualifying announcement must be official and public. Any rumored or private statements of intention will not qualify.
Any announcement that the drug has been reclassified to Category 1 will qualify. Any announcement within this market’s timeframe of future intention to reclassify to Category 1 will qualify regardless of whether the reclassification has happened by the listed date.
A qualifying reclassification must be to Category 1 of the Bulk Drug Substances List or an equivalent classification that allows interim compounding of the drug. Removal from a different category will not qualify.
The resolution source for this market will be official statements from the FDA; however, a consensus of credible reporting will also be used.
A qualifying announcement must be official and public. Any rumored or private statements of intention will not qualify.
Any announcement that the drug has been reclassified to Category 1 will qualify. Any announcement within this market’s timeframe of future intention to reclassify to Category 1 will qualify regardless of whether the reclassification has happened by the listed date.
A qualifying reclassification must be to Category 1 of the Bulk Drug Substances List or an equivalent classification that allows interim compounding of the drug. Removal from a different category will not qualify.
The resolution source for this market will be official statements from the FDA; however, a consensus of credible reporting will also be used.
交易量
$2,789结束日期
2026-12-31市场开放时间
Jun 22, 2026, 10:10 PM ETResolver
0x65070BE91...The FDA regulates BPC-157, a research peptide used for tissue repair and gastrointestinal applications, through its 503A bulk drug substances lists for pharmacy compounding. Previously placed in Category 2 due to immunogenicity risks, impurity concerns, and limited human safety data, the substance was removed from that list in April 2026 after nomination withdrawals, leaving it in regulatory limbo. At the July 23-24, 2026 Pharmacy Compounding Advisory Committee meeting, the panel voted 8-6 (with one abstention) to recommend inclusion on the 503A bulks list, which would enable Category 1 status and interim compounding eligibility. The FDA has not yet issued a final determination, and any move to Category 1 would require agency rulemaking. Traders monitor this process alongside potential future PCAC reviews or policy shifts for resolution timing.
基于Polymarket数据的AI实验性摘要。这不是交易建议，也不影响该市场的结算方式。 · 更新于
警惕外部链接哦。
警惕外部链接哦。
常见问题